American Journal of Cardiology
Volume 108, Issue 3 , Pages 360-366, 1 August 2011

Relation of Increased Prebeta-1 High-Density Lipoprotein Levels to Risk of Coronary Heart Disease

  • Lin T. Guey, PhD

      Affiliations

    • Applied Quantitative Genotherapeutics, Pfizer Pharmaceuticals, Cambridge, Massachusetts
  • ,
  • Clive R. Pullinger, PhD

      Affiliations

    • Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California
  • ,
  • Brian Y. Ishida, PhD

      Affiliations

    • Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California
  • ,
  • Patricia M. O'Connor, MD

      Affiliations

    • University of Limerick, Limerick, Ireland
  • ,
  • Christian Zellner, MD

      Affiliations

    • Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California
  • ,
  • Omar L. Francone, PhD

      Affiliations

    • Cardiovascular, Metabolic and Endocrine Diseases, Pfizer Pharmaceuticals, Groton, Connecticut
  • ,
  • Jason M. Laramie, PhD

      Affiliations

    • Applied Quantitative Genotherapeutics, Pfizer Pharmaceuticals, Cambridge, Massachusetts
  • ,
  • Josefina M. Naya-Vigne, MD

      Affiliations

    • Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California
  • ,
  • Ketevan A. Siradze, MD

      Affiliations

    • Genentech, Inc., South San Francisco, California
  • ,
  • Prakash Deedwania, MD

      Affiliations

    • Veterans Affairs Central California Health Care System/UCSF, Fresno, California
  • ,
  • Rita F. Redberg, MD

      Affiliations

    • Department of Medicine, University of California, San Francisco, San Francisco, California
  • ,
  • Philip H. Frost, MD

      Affiliations

    • Department of Medicine, University of California, San Francisco, San Francisco, California
  • ,
  • Albert B. Seymour, PhD

      Affiliations

    • Applied Quantitative Genotherapeutics, Pfizer Pharmaceuticals, Cambridge, Massachusetts
  • ,
  • John P. Kane, MD, PhD

      Affiliations

    • Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California
  • ,
  • Mary J. Malloy, MD

      Affiliations

    • Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California
    • Corresponding Author InformationCorresponding author: Tel: 415-476-2754; fax: 415-502-5658

Received 12 January 2011; received in revised form 18 March 2011; accepted 18 March 2011.

Preβ-1 high-density lipoprotein (HDL) plays a key role in reverse cholesterol transport by promoting cholesterol efflux. Our aims were (1) to test previous associations between preβ-1 HDL and coronary heart disease (CHD) and (2) to investigate whether preβ-1 HDL levels also are associated with risk of myocardial infarction (MI). Plasma preβ-1 HDL was measured by an ultrafiltration–isotope dilution technique in 1,255 subjects recruited from the University of California–San Francisco Lipid and Cardiovascular Clinics and collaborating cardiologists. Preβ-1 HDL was significantly and positively associated with CHD and MI even after adjustment for established risk factors. Inclusion of preβ-1 HDL in a multivariable model for CHD led to a modest improvement in reclassification of subjects (net reclassification index 0.15, p = 0.01; integrated discrimination improvement 0.003, p = 0.2). In contrast, incorporation of preβ-1 HDL into a risk model of MI alone significantly improved reclassification of subjects (net reclassification index 0.21, p = 0.008; integrated discrimination improvement 0.01, p = 0.02), suggesting that preβ-1 HDL has more discriminatory power for MI than for CHD in our study population. In conclusion, these results confirm previous associations between preβ-1 HDL and CHD in a large well-characterized clinical cohort. Also, this is the first study in which preβ-1 HDL was identified as a novel and independent predictor of MI above and beyond traditional CHD risk factors.

 

 This work was supported in part by Grants HL3120, HL50782, Hl50779, and AA11205 from the National Institutes of Health, Bethesda, Maryland; Foundation Leducq, Paris, France; Campini Foundation, San Francisco, California; Joseph Drown Foundation, Los Angeles, California; and a gift from Donald Yellon, San Francisco, California.

PII: S0002-9149(11)01349-X

doi:10.1016/j.amjcard.2011.03.054

American Journal of Cardiology
Volume 108, Issue 3 , Pages 360-366, 1 August 2011